<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Mol Brain</journal-id>
<journal-id journal-id-type="iso-abbrev">Mol Brain</journal-id>
<journal-title-group>
<journal-title>Molecular Brain</journal-title>
</journal-title-group>
<issn pub-type="epub">1756-6606</issn>
<publisher>
<publisher-name>BioMed Central</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30935412</article-id>
<article-id pub-id-type="pmc">6444596</article-id>
<article-id pub-id-type="publisher-id">452</article-id>
<article-id pub-id-type="doi">10.1186/s13041-019-0452-5</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Prenatal selective serotonin reuptake inhibitor (SSRI) exposure induces working memory and social recognition deficits by disrupting inhibitory synaptic networks in male mice</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Yu</surname>
<given-names>Weonjin</given-names>
</name>
<address>
<email>gmsyw@nus.edu.sg</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Yen</surname>
<given-names>Yi-Chun</given-names>
</name>
<address>
<email>yichunyen@gmail.com</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lee</surname>
<given-names>Young-Hwan</given-names>
</name>
<address>
<email>younghwan.lee@u.duke.nus.edu</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tan</surname>
<given-names>Shawn</given-names>
</name>
<address>
<email>shawn.tan@duke-nus.edu.sg</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xiao</surname>
<given-names>Yixin</given-names>
</name>
<address>
<email>yixin.xiao@duke-nus.edu.sg</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lokman</surname>
<given-names>Hidayat</given-names>
</name>
<address>
<email>hidayat.lokman@duke-nus.edu.sg</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ting</surname>
<given-names>Audrey Khoo Tze</given-names>
</name>
<address>
<email>audrey.khoo@u.duke.nus.edu</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ganegala</surname>
<given-names>Hasini</given-names>
</name>
<address>
<email>hasini.ganegala@duke-nus.edu.sg</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kwon</surname>
<given-names>Taejoon</given-names>
</name>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Ho</surname>
<given-names>Won-Kyung</given-names>
</name>
<address>
<email>wonkyung@snu.ac.kr</email>
</address>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Je</surname>
<given-names>H. Shawn</given-names>
</name>
<address>
<phone>65-6601-1260</phone>
<email>shawn.je@duke-nus.edu.sg</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0385 0924</institution-id><institution-id institution-id-type="GRID">grid.428397.3</institution-id><institution>Molecular Neurophysiology Laboratory, Signature Program in Neuroscience and Behavioral Disorders, </institution><institution>Duke-National University of Singapore (NUS) Medical School, </institution></institution-wrap>8 College Road, Singapore, 169857 Singapore </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0470 5905</institution-id><institution-id institution-id-type="GRID">grid.31501.36</institution-id><institution>Department of Physiology, </institution><institution>Seoul National University College of Medicine, </institution></institution-wrap>Seoul, 03080 Republic of Korea </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2180 6431</institution-id><institution-id institution-id-type="GRID">grid.4280.e</institution-id><institution>Department of Physiology, Yong Loo Lin School of Medicine, </institution><institution>National University of Singapore, </institution></institution-wrap>Singapore, 117597 Singapore </aff>
<aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0381 814X</institution-id><institution-id institution-id-type="GRID">grid.42687.3f</institution-id><institution>Department of Biomedical Engineering, School of Life Science, </institution><institution>Ulsan National Institute of Science and Technology (UNIST), </institution></institution-wrap>UNIST-gil 50, Ulsan, 44919 Republic of Korea </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>1</day>
<month>4</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>1</day>
<month>4</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>12</volume>
<elocation-id>29</elocation-id>
<history>
<date date-type="received">
<day>13</day>
<month>12</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>3</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Â© The Author(s). 2019</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p id="Par1">Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed antidepressant drugs in pregnant women. Infants born following prenatal exposure to SSRIs have a higher risk for behavioral abnormalities, however, the underlying mechanisms remains unknown. Therefore, we examined the effects of prenatal fluoxetine, the most commonly prescribed SSRI, in mice. Intriguingly, chronic in utero fluoxetine treatment impaired working memory and social novelty recognition in adult males. In the medial prefrontal cortex (mPFC), a key region regulating these behaviors, we found augmented spontaneous inhibitory synaptic transmission onto the layer 5 pyramidal neurons. Fast-spiking interneurons in mPFC exhibited enhanced intrinsic excitability and serotonin-induced excitability due to upregulated serotonin (5-HT) 2A receptor (5-HT<sub>2A</sub>R) signaling. More importantly, the behavioral deficits in prenatal fluoxetine treated mice were reversed by the application of a 5-HT<sub>2A</sub>R antagonist. Taken together, our findings suggest that alterations in inhibitory neuronal modulation are responsible for the behavioral alterations following prenatal exposure to SSRIs.</p>
<sec>
<title>Electronic supplementary material</title>
<p>The online version of this article (10.1186/s13041-019-0452-5) contains supplementary material, which is available to authorized users.</p>
</sec>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Prenatal</kwd>
<kwd>Serotonin (5-HT)</kwd>
<kwd>Selective serotonin reuptake inhibitor (SSRI)</kwd>
<kwd>Fluoxetine</kwd>
<kwd>Working memory</kwd>
<kwd>Social recognition</kwd>
<kwd>Serotonin 2A receptor (5-HT<sub>2A</sub>R)</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001459</institution-id>
<institution>Ministry of Education - Singapore</institution>
</institution-wrap>
</funding-source>
<award-id>MOE2012-T2-1-021, MOE2014-T2-2-071</award-id>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001348</institution-id>
<institution>Agency for Science, Technology and Research</institution>
</institution-wrap>
</funding-source>
<award-id>TCRP, 13/1/96/688</award-id>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002613</institution-id>
<institution>Ulsan National Institute of Science and Technology</institution>
</institution-wrap>
</funding-source>
<award-id>1.170009.01</award-id>
<principal-award-recipient>
<name>
<surname>Kwon</surname>
<given-names>Taejoon</given-names>
</name>
</principal-award-recipient>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>
<institution>National Medical Research Council (SG)</institution>
</funding-source>
<award-id>NMRC/OFIRG/0050/2017, NMRC/TCR/013-NNI/2014</award-id>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>
<institution>National Research Foundation Singapore (SG)</institution>
</funding-source>
<award-id>NRF-CRP17-2017-04</award-id>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>Â© The Author(s) 2019</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Introduction</title>
<p id="Par19">Anti-depressants are commonly prescribed to treat major depression and post-traumatic stress disorder. Currently, 17% of pregnant women experience major depression, and approximately 10% of these women use anti-depressants [<xref ref-type="bibr" rid="CR1">1</xref>â<xref ref-type="bibr" rid="CR3">3</xref>]. The most commonly prescribed anti-depressants, selective serotonin reuptake inhibitors (SSRIs), are believed to increase the ambient level of 5-hydrotryptamine (5-HT, serotonin) in synaptic clefts by preventing its reabsorption [<xref ref-type="bibr" rid="CR4">4</xref>â<xref ref-type="bibr" rid="CR6">6</xref>]. However, the exact mechanism by which SSRIs mitigates depression remains unknown. A recent systematic review showed that the potential adverse effects of SSRIs might outweigh their beneficial effects on depression [<xref ref-type="bibr" rid="CR7">7</xref>â<xref ref-type="bibr" rid="CR9">9</xref>]. In addition, fluoxetine (FLX), one of the most widely used SSRIs with a moderately long half-life (t <sub>Â½</sub>â=â48âh), can cross the placental and blood-brain barriers and is also detected in breast milk, suggesting potential accumulation of FLX as well as 5-HT in the fetal brain [<xref ref-type="bibr" rid="CR10">10</xref>]. However, little is known about the safety of FLX use during pregnancy. Moreover, the long-term consequences of prenatal FLX exposure for adverse behavioral outcomes in offspring are uncertain and sometimes conflicting; these conflicting findings are likely due to the independent association between maternal depression and negative pregnancy outcomes in human [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>].</p>
<p id="Par20">Ansorge et al. firstly observed that postnatal FLX exposure produced anxiety behaviors and disrupted learning in rodent offspring [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. In subsequent studies, manipulations of brain 5-HT levels during early development produced abnormal neuronal circuit formation in the cortex and promoted aggressive or anxiety-related behaviors [<xref ref-type="bibr" rid="CR15">15</xref>â<xref ref-type="bibr" rid="CR19">19</xref>]. However, a thorough assessment of animal behaviors induced by prenatal SSRI exposure has not been performed. Furthermore, the underlying molecular and circuit mechanisms of these behavioral changes have not been investigated and, for this reason, no rescue experiment has been performed in offspring exposed to SSRIs during prenatal period.</p>
<p id="Par21">Using a combination of behavioral analyses and electrophysiological investigations of affected neuronal circuits, we examined how chronic prenatal exposure to exogenous FLX influences animal behaviors and neuronal circuitry and function. We observed impaired social recognition and working memory in male mice chronically exposed to FLX. Furthermore, we observed reduced frequencies in spontaneous excitatory postsynaptic currents recorded from layer (L) 5 pyramidal neurons in the prelimbic cortex of affected mice. Intriguingly, these reduced excitatory neuronal activities were caused by enhanced serotonergic modulation of fast-spiking (FS) interneurons in L5 due to enhanced 5-HT<sub>2A</sub> receptors (5-HT<sub>2A</sub>Rs). Moreover, the acute treatment with the 5-HT<sub>2A</sub>R antagonist MDL100907 (MDL) normalized the impaired social recognition and working memory impairment in these animals [<xref ref-type="bibr" rid="CR20">20</xref>].</p>
</sec>
<sec id="Sec2">
<title>Results</title>
<sec id="Sec3">
<title>Prenatal fluoxetine treatment induced deficits in working memory and social recognition</title>
<p id="Par22">We subjected pregnant mice to daily intraperitoneal (i.p.) injections of 0.6âmg/kg FLX or saline (SAL) from embryonic day (ED) 4 to ED19 to examine behavioral changes in mice exposed to SSRIs during the prenatal period (Fig.Â <xref ref-type="fig" rid="Fig1">1</xref>a) [<xref ref-type="bibr" rid="CR21">21</xref>]. The mean number of pups born per litter, percentages of male pups per litter, and average body weights of mice at postnatal day 21 (P21) and P60 were not significantly different between FLX-treated litters and SAL-treated, control litters (TableÂ <xref ref-type="table" rid="Tab1">1</xref>). The FLX-treated mice exhibited normal spontaneous exploratory behavior in terms of the total distance traveled (AdditionalÂ fileÂ <xref ref-type="media" rid="MOESM1">1</xref>: Figure S1A), but spent less time in the center zone (t<sub>(26)</sub> =2.12, <italic>p</italic>â&lt;â0.001; Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Figure S1B), indicating a potential sign of anxiety-like behaviors. We tested the mice using the elevated zero maze and light-dark box test to examine anxiety-like behaviors (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Figures S1C, D). However, FLX-treated mice did not exhibit differences in the time spent in the open arms of the elevated zero maze (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Figure S1C) or total transitions in the light-dark box (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Figure S1D), suggesting normal anxiety levels in FLX-treated mice.<fig id="Fig1"><label>Fig. 1</label><caption><p>Prenatal exposure to fluoxetine induces deficits in executive functions in male offspring. (<bold>a</bold>) Schematic diagram of the experimental design. From embryonic day 4 (ED4) to ED19, pregnant females received daily injections of either fluoxetine (FLX, 0.6âmg/kg/day) or saline (SAL). Male offspring were subjected to behavioral testing at 8â12âweeks of age. (<bold>b</bold>) Bar plot of spontaneous alternation rate on the Y-maze. (<bold>c</bold>) Bar plot of the total number of entries into all arms of the Y-maze. (<bold>d</bold>) Representative heat map images of results of the three-chamber social interaction test with a novel mouse and object. The occupancy rate was normalized to the region with peak occupancy in the arena. (<bold>e</bold>) Bar plot of the time spent sniffing the novel mouse and object in the three-chamber social interaction task. (<bold>f</bold>) Bar plot of the social preference index (time spent sniffing mouse/total time spent sniffing the mouse and the object). The dotted line indicates an equal preference (50%) (<bold>g</bold>) Representative heat map images of the results of the three-chamber social interaction tests with a familiar mouse and novel mouse. (<bold>h</bold>) Bar plot of the times spent sniffing the familiar mouse and novel mouse in the three-chamber social interaction task. (<bold>i</bold>) Bar plot of the social novelty preference index (time spent sniffing the novel mouse/total time spent sniffing both mice). Data are presented as means Â± SEM. (<bold>e</bold>) and (<bold>h</bold>) Two-way repeated measures ANOVA. (<bold>b</bold>), (<bold>c</bold>), (<bold>f</bold>) and (<bold>i</bold>) Unpaired t-test. * <italic>p</italic>â&lt;â0.05, ** <italic>p</italic>â&lt;â0.01, *** <italic>p</italic>â&lt;â0.001</p></caption><graphic id="MO1" xlink:href="13041_2019_452_Fig1_HTML"></graphic></fig><table-wrap id="Tab1"><label>Table 1</label><caption><p>Effects of prenatal SAL and FLX treatment on number, gender composition and weight of offspring</p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th>SAL</th><th>FLX</th></tr></thead><tbody><tr><td>Total number of litters</td><td>22</td><td>23</td></tr><tr><td>Total number of offspring</td><td>104</td><td>96</td></tr><tr><td>Total number of male mice</td><td>58</td><td>49</td></tr><tr><td>Average number of pups per litter</td><td>4.73âÂ±â0.44</td><td>4.17âÂ±â0.37</td></tr><tr><td>Average number of male pups per litter</td><td>2.64âÂ±â0.33</td><td>2.13âÂ±â0.21</td></tr><tr><td>Percentage of male pups in each litter</td><td>55.88âÂ±â4.98%</td><td>54.26âÂ±â4.19%</td></tr><tr><td>Weight of male mice at P28</td><td>16.44âÂ±â0.41âg, <italic>n</italic>â=â20</td><td>15.89âÂ±â0.33âg, <italic>n</italic>â=â23</td></tr></tbody></table></table-wrap></p>
<p id="Par23">To further examine the role of prenatal FLX in working memory and cognitive function, we subjected FLX-treated mice to the Y-maze spontaneous alternation task [<xref ref-type="bibr" rid="CR22">22</xref>]. Briefly, both control and FLX treated mice were allowed to freely access three arms of the Y-maze for 10âmin. Mice prefer to explore a previously uncharted arm of the maze rather than returning to a previously visited arm [<xref ref-type="bibr" rid="CR23">23</xref>]. Intriguingly, the alternation rate of prenatally FLX-treated mice was lower than that of SAL-treated mice (t [<xref ref-type="bibr" rid="CR24">24</xref>] =3.05, <italic>p</italic>â&lt;â0.01; Fig. <xref ref-type="fig" rid="Fig1">1</xref>b) without changes in general activity, as measured by the total arm entries (<italic>p</italic>â&gt;â0.05; Fig. <xref ref-type="fig" rid="Fig1">1</xref>c). To test whether this reduced alternation rate was due to either behavioral perseverance or recognition of a new environment, we performed the novel object recognition test. Interestingly, both prenatally SAL- and FLX-treated mice were able to distinguish the novel and familiar objects, as assessed by the time spent exploring the novel object (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Figure S1E). Additionally, there was no significant difference in grooming behaviors between the two groups, indicating that the behavioral perseverance of FLX-treated mice was not associated with repetitive or obsessive-compulsive behaviors (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Figure S1F).</p>
<p id="Par24">Next, we subjected the two groups of mice to the social interaction test by using a 3-chamber apparatus [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. During the 10-min habituation phase, neither groups showed any side preference in the 3-chamber apparatus as reflected by the lack of differences in the time spent sniffing two empty wire pencil holders in the left and right chambers (<italic>p</italic>â&gt;â0.05; Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Figures S1G, H). Over the next 10âmin, both groups spent significantly more time sniffing the juvenile male mouse (social stimulus) than the dummy object (<italic>t</italic> [<xref ref-type="bibr" rid="CR9">9</xref>] =7.72, <italic>p</italic>â&lt;â0.001 for SAL; <italic>t</italic> [<xref ref-type="bibr" rid="CR9">9</xref>] =10.39, <italic>p</italic>â&lt;â0.001 for FLX; Fig. <xref ref-type="fig" rid="Fig1">1</xref>d-f). During the last 10âmin, prenatally SAL-treated mice spent significantly more time sniffing the novel juvenile male mouse than the familiar juvenile mouse (<italic>t</italic> [<xref ref-type="bibr" rid="CR9">9</xref>] =3.28, <italic>p</italic>â&lt;â0.01), confirming a preference for social novelty in SAL mice. In contrast, prenatally FLX-treated mice failed to show this preference, as indicated by the similar time spent in investigating the novel and familiar juvenile mice (<italic>t</italic> [<xref ref-type="bibr" rid="CR9">9</xref>] = 0.25, <italic>p</italic>â=â0.81; Fig. <xref ref-type="fig" rid="Fig1">1</xref>g-i). Taken together, these data indicate that prenatally FLX-treated mice exhibited deficits in working memory and social novelty recognition.</p>
</sec>
<sec id="Sec4">
<title>Increased frequency of spontaneous and miniature inhibitory synaptic currents in layer 5 pyramidal neurons in the prefrontal cortex of FLX-treated mice</title>
<p id="Par25">Although the circuit mechanism underlying social behavior phenotypes observed in prenatally FLX-treated mice is not obvious [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>], the deficits in working memory observed in the Y-maze spontaneous alternation task prompted us to characterize neuronal activities in the prefrontal cortex (PFC), which is functionally analogous to the dorsolateral PFC, a critical area known for working memory in humans [<xref ref-type="bibr" rid="CR29">29</xref>]. Within the PFC, information is transmitted top-down via pathways from L2/3 pyramidal neurons to pyramidal neurons in L5 [<xref ref-type="bibr" rid="CR30">30</xref>]. We first characterized the morphology of L5 pyramidal neurons, which send the major corticofugal outputs from the PFC network. We did not observe any differences in layer formation, the number of neurons, dendritic complexity, and the number of dendritic spines in L5 pyramidal neurons between FLX-treated and SAL-treated mice (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Figure S2). Next, using whole-cell patch-clamp recordings, we characterized the intrinsic properties of L5 pyramidal neurons within the prelimbic area (PrL), which is homologous to the dorsolateral PFC in primates [<xref ref-type="bibr" rid="CR30">30</xref>]. We first measured spontaneous excitatory postsynaptic currents (sEPSCs) in L5 pyramidal neurons (Fig.Â <xref ref-type="fig" rid="Fig2">2</xref>a-c). The frequency of sEPSCs recorded from FLX-treated mice was significantly decreased by 18% compared with those recorded from SAL-treated mice, whereas the amplitude of sEPSCs was unaltered (SAL: 10.46âÂ±â0.50âHz, 15.23âÂ±â0.92 pA; FLX: 8.56âÂ±â0.51âHz, 15.32âÂ±â1.45 pA) (Fig. <xref ref-type="fig" rid="Fig2">2</xref>a-c). This indicates that spontaneous excitatory synaptic transmission in the PFC was decreased in FLX-treated mice. To further explore the mechanism of changes in sEPSCs in FLX-treated mice, we recorded miniature excitatory postsynaptic currents (mEPSCs) and the neuronal excitability of L5 pyramidal neurons. Intriguingly, the frequency and amplitude of mEPSCs recorded from FLX-treated mice were not significantly different from mEPSCs recorded from SAL-treated mice (SAL: 6.34âÂ±â0.60âHz, 15.61âÂ±â2.01 pA; FLX: 6.80âÂ±â0.34âHz, 15.53âÂ±â1.11 pA) (Fig. <xref ref-type="fig" rid="Fig2">2</xref>d-f). More strikingly, most parameters of intrinsic neuronal properties (input resistance, resting membrane potentials, afterhyperpolarization amplitude, and the threshold of action potentials (APs)) of the L5 neurons of FLX-treated mice were not significantly altered (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Figure S3). These data indicate that the decreased spontaneous excitatory network activities did not arise from intrinsic changes in excitatory neurons in the prefrontal cortex of FLX-treated mice.<fig id="Fig2"><label>Fig. 2</label><caption><p>Fluoxetine induces an increase in the number of inhibitory inputs to excitatory neurons and reduced excitatory basal transmission in the L5 pyramidal neurons of the prelimbic cortex of FLX-treated mice. (<bold>a</bold>) Representative current traces depicting spontaneous excitatory post-synaptic currents (sEPSCs) obtained from L5 pyramidal neurons in the prelimbic cortex (PrL) pyramidal neurons of SAL- and FLX-treated (red) mice. (<bold>b</bold> and <bold>c</bold>) Plots of the cumulative distributions of sEPSC (<bold>b</bold>) amplitudes and (<bold>c</bold>) inter-event intervals obtained from SAL- (black) and FLX-treated (red) mice. (<bold>d</bold>) Representative current traces depicting mEPSCs obtained from SAL- and FLX-treated mice. (<bold>e</bold> and <bold>f</bold>) Plots of the cumulative distribution plots of mEPSC (<bold>e</bold>) amplitudes and (<bold>f</bold>) inter-event intervals. (<bold>g</bold>) Representative current traces depicting sIPSCs obtained from SAL- and FLX-treated mice. (<bold>h</bold> and <bold>i</bold>) Plots of the cumulative distribution plots of sIPSC (<bold>h</bold>) amplitudes and (<bold>i</bold>) inter-event intervals. (<bold>j</bold>) Representative current traces depicting mIPSCs obtained from SAL- and FLX-treated mice. (<bold>k</bold> and <bold>l</bold>) Plots of the cumulative distribution of mIPSC (<bold>k</bold>) amplitudes and (<bold>l</bold>) inter-event intervals. Data are presented as meanâÂ±âSEM. All data were analyzed using the Mann-Whitney U test. *<italic>p</italic>â&lt;â0.05, **<italic>p</italic>â&lt;â0.01</p></caption><graphic id="MO2" xlink:href="13041_2019_452_Fig2_HTML"></graphic></fig></p>
<p id="Par26">To test whether inhibitory synaptic transmission in the PFC was affected in FLX-treated mice, we recorded both spontaneous and miniature inhibitory postsynaptic currents (sIPSCs and mIPSCs, respectively) in L5 pyramidal neurons within the PrL [<xref ref-type="bibr" rid="CR30">30</xref>]. Surprisingly, we observed a significant increase in the frequency of sIPSCs (SAL: 22.46âÂ±â0.72âHz; FLX: 29.99âÂ±â0.96âHz, <italic>p</italic>â&lt;â0.01), but not the amplitude (SAL: 36.88âÂ±â4.57 pA; FLX: 39.29âÂ±â3.36 pA) (Fig. <xref ref-type="fig" rid="Fig2">2</xref>g-i). In contrast, neither the frequency nor the amplitude of mIPSCs were affected in L5 neurons from FLX-treated mice (Fig. <xref ref-type="fig" rid="Fig2">2</xref>j-l). These data indicate that prenatal FLX exposure increased spontaneous inhibitory network activity in L5 pyramidal neurons within the PrL.</p>
</sec>
<sec id="Sec5">
<title>Increased excitability and serotonergic modulation of L5 fast-spiking interneurons in PrL of FLX-treated mic</title>
<p id="Par27">The mPFC receives dense serotonergic innervation from the raphe nuclei, and both pyramidal and interneurons within the mPFC express several 5-HT receptor subtypes, with a particularly high density of 5-HT1<sub>A</sub> and 5-HT2<sub>A</sub>Rs [<xref ref-type="bibr" rid="CR31">31</xref>â<xref ref-type="bibr" rid="CR33">33</xref>]. Chronic increases in ambient synaptic 5-HT due to SSRI-mediated blockade of the serotonin transporter (5-HTT) could potentially result in desensitization, internalization, or compensatory level changes via transcription and translations of certain 5-HT receptors [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. To test this hypothesis, qRT-PCR was performed on the PrL tissues from either SAL-treated or FLX-treated dams. The qRT-PCR results showed a significant increase in the levels of the 5-HT<sub>2A</sub>R mRNAs (SAL vs FLX fold change in 5-HT<sub>2A</sub>R: 1.49âÂ±â0.14; <italic>p</italic>â=â0.044, unpaired t-test; SAL, <italic>n</italic>â=â5; FLX, <italic>n</italic>â=â5). Although not statistically significant, there was an upward trend in the level of the 5-HT<sub>1A</sub>R mRNAs (SAL vs FLX fold change in 5-HT<sub>1A</sub>R: 1.48âÂ±â0.17; <italic>p</italic>â=â0.054, unpaired t-test; SAL, <italic>n</italic>â=â5; FLX, <italic>n</italic>â=â5)(Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Figures S4A, B). In contrast, we did not observe any significant changes in the mRNA expression levels of other 5-HT receptors and transporters in both qRT-PCR and microarray analyses (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Figures S4C, D).</p>
<p id="Par28">We wondered whether the upregulation of 5-HT <sub>2A</sub>Rs resulted in increased spontaneous inhibitory synaptic transmission in L5 excitatory pyramidal neurons. To address this question, we first investigated functional changes in sIPSCs recorded from L5 pyramidal neurons upon acute exogenous 5-HT treatment. Consistent with results from previous studies [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>], treatment with exogenous 5-HT (30âÎ¼M) significantly enhanced both the frequency and amplitude of sIPSCs in L5 pyramidal neurons in SAL-treated mice by 32.74âÂ±â6.65% and 29.22âÂ±â11.09%, respectively (nâ=â5, <italic>p</italic>â&lt;â0.05, Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Figures S4E, F). Intriguingly, L5 pyramidal neurons in FLX-treated mice exhibited substantial increases in the frequency and amplitude of sIPSCs (53.25%âÂ±â7.85 and 36.93âÂ±â6.22%, <italic>n</italic>â=â5, <italic>p</italic>â&lt;â0.05, Additional file <xref ref-type="media" rid="MOESM1">1</xref>, Figures S4E, F).</p>
<p id="Par29">Next, we recorded the intrinsic excitability and firing properties of FS inhibitory neurons before and after 5-HT application to further investigate the effects of 5-HT on L5 FS inhibitory neurons that are critical for shaping cortical circuit activity by projecting their inhibitory outputs onto the L5 pyramidal neurons within the PFC [<xref ref-type="bibr" rid="CR37">37</xref>â<xref ref-type="bibr" rid="CR39">39</xref>](Fig.Â <xref ref-type="fig" rid="Fig3">3</xref>a). As shown by immunohistochemical staining, the recorded FS interneurons were positive for parvalbumin (PV) (Fig. <xref ref-type="fig" rid="Fig3">3</xref>b) and exhibited a characteristic 224-Hz firing at a 450pA current injection (Fig. <xref ref-type="fig" rid="Fig3">3</xref>c). Next, we applied a series of incremental square depolarizing pulses to L5 FS neurons from SAL or FLX mice before and during 5-HT application (Fig. <xref ref-type="fig" rid="Fig3">3</xref>c-g). 5-HT application significantly increased the spike frequency of L5 FS neurons at each injected current step in both SAL and FLX mice, and this increase in spike frequency was normalized after washout. Intriguingly, compared with L5 FS neurons from the SAL group, L5 FS neurons from the FLX group showed a larger increase in spike frequency in response to the 5-HT treatment (SAL: 38.57âÂ±â5.4% vs FLX: 92.05âÂ±â17.99%) (Fig. <xref ref-type="fig" rid="Fig3">3</xref>d-g). This increased frequency observed in L5 FS neurons was abolished by a subsequent treatment with MDL, a specific antagonist of 5-HT<sub>2A</sub>Rs (1âÎ¼M), indicating that the increased responsiveness of 5-HT<sub>2A</sub>R in L5 FS neurons resulted in a 5-HT-dependent increase in AP frequency (Fig. <xref ref-type="fig" rid="Fig3">3</xref>d-g). In contrast, co-treatment with 5-HT<sub>1A</sub>R antagonists (WAY-100135, 10âÎ¼M) and 5-HT did not affect 5-HT-mediated changes in the spike frequency of L5 FS interneurons (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Figures S5A-D). Thus, 5-HT-mediated changes in acute spike frequency were modulated by 5-HT<sub>2A</sub>Rs in the L5 FS interneurons of FLX-treated mice and subsequently increased sIPSCs in L5 pyramidal neurons.<fig id="Fig3"><label>Fig. 3</label><caption><p>Increased excitability and serotonergic modulation of FS interneurons in PrL of FLX-treated mice. (<bold>a</bold>) Schematic diagram of the mouse PFC as outlined by the red dashed lines. The black box indicates a high magnification view of the neurons that were patched. We performed whole-cell patch-clamp recordings of putative fast-spiking (FS) interneurons in L5 of the PrL. (<bold>b</bold>) Representative image of a biocytin-filled FS interneuron in L5. Inset â co-staining for biocytin and parvalbumin, a marker of FS interneurons. (<bold>c</bold>) Characteristic responses of FS interneurons from SAL-treated mice to current injections (ââ450 pA, 200 pA, and 450 pA) showing low adaptation to repeated firing. (<bold>d</bold>) Representative traces of FS interneurons from SAL-treated mice showing responses to current injections (200 pA) at baseline (CTRL), during the bath application of 5-HT (5-HT), and the bath application of the 5-HT<sub>2A</sub>R antagonist MDL. (<bold>e</bold>) Bar plot summarizing the effects of the 5-HT and MDL treatment on FS interneurons in SAL-treated mice (<bold>f</bold>) Representative traces of FS interneurons from FLX-treated mice show the responses to current injections (200 pA) under CTRL, 5-HT and MDL conditions. (<bold>g</bold>) Bar plot summarizing the effects of the 5-HT and MDL treatments on FS interneurons in FLX-treated mice. Data are presented as means Â± SEM. All data were analyzed using the Wilcoxon signed ranks test. **<italic>p</italic>â&lt;â0.01</p></caption><graphic id="MO3" xlink:href="13041_2019_452_Fig3_HTML"></graphic></fig></p>
<p id="Par30">We further tested the effect of 5-HT treatment on L5 pyramidal neurons. Compared with FS interneurons, L5 pyramidal neurons showed a significantly reduced spike frequency in response to 5-HT application (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Figures S6A-C). Furthermore, no significant difference in the 5-HT-mediated reduction in the sEPSC frequency in L5 pyramidal neurons was observed between SAL- and FLX-treated mice (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Figures S6D, G).</p>
</sec>
<sec id="Sec6">
<title>Behavioral deficits of FLX-treated mice were ameliorated by acute treatment with 5-HT<sub>2A</sub>R antagonists</title>
<p id="Par31">Upregulation of 5-HT<sub>2A</sub>R signaling in PV neurons suppressed spontaneous network firing in L5 PFC microcircuits, resulting in the poor performance of FLX-treated mice on working memory and social recognition tests. Therefore, we examined whether the selective suppression of 5-HT<sub>2A</sub>R signaling would enhance the performance of FLX-treated mice in the spontaneous alternation test and social novelty recognition tests (Fig.Â <xref ref-type="fig" rid="Fig4">4</xref>a). I.P. injection of a 5-HT<sub>2A</sub>R antagonist (MDL) did not influence the general behavior of wild-type animals, when they tested in the open-field test and elevated zero maze at a given dosage (data not shown), but the application of the same dosage of MDL sufficiently reversed 5-HT-mediated changes in the excitability of L5 FS interneurons from FLX-treated mice (Fig. <xref ref-type="fig" rid="Fig3">3</xref>g). Intriguingly, acute administration of MDL effectively reversed the poor performance of FLX-treated mice on the Y-maze spontaneous alternation task (Fig. <xref ref-type="fig" rid="Fig4">4</xref>b, c). Furthermore, the acute MDL treatment did not alter the social preference index in FLX-treated mice (Fig. <xref ref-type="fig" rid="Fig4">4</xref>d-f), but rescued deficits in the novel recognition task in FLX-treated mice (Fig. <xref ref-type="fig" rid="Fig4">4</xref>g-h). Taken together, our data revealed that the acute suppression of augmented 5-HT<sub>2A</sub>R signaling in FLX-treated mice could rescue their behavioral deficits in working memory and social recognition memory.<fig id="Fig4"><label>Fig. 4</label><caption><p>Prenatal FLX-induced deficits in executive function are rescued by a 5-HT<sub>2A</sub>R antagonist. (<bold>a</bold>) Schematic diagram of the drug treatment procedure. Prenatally SAL-treated mice were injected with vehicle (VEH), whereas prenatally fluoxetine (FLX)-treated mice were randomly assigned to VEH and 5-HT<sub>2A</sub>R antagonist (MDL) groups. Thirty minutes before behavioral testing, FLX mice received i.p. injections of either vehicle (0.5% DMSO) or MDL (0.01âmg/kg in 0.5% DMSO). (<bold>b</bold>) Bar plot of spontaneous alternation rates of SAL-treated mice that were administered VEH (black) and FLX-treated mice that were administered VEH (red) or MDL (blue) in the Y-maze. (<bold>c</bold>) Bar plot of the total number of entries into all arms of the Y-maze. (<bold>d</bold>) Representative heat map of results of the three-chamber social interaction test with a novel mouse and object. The occupancy rate was normalized to the region with peak occupancy in the arena. (<bold>e</bold>) Bar plot of the times spent sniffing the novel mouse and object in the three-chamber social interaction task. (<bold>f</bold>) Bar plot of the social preference index (time spent sniffing the mouse/total time spent sniffing the mouse and the object). The dotted line indicates an equal preference (50%) (<bold>g</bold>) Representative heat map of results from the three-chamber social interaction test with a familiar mouse and novel mouse. (H) Bar plot of the times spent sniffing the familiar mouse and a novel mouse in the three-chamber social interaction task. (<bold>i</bold>) Bar plot of the social novelty preference index (time spent sniffing the novel mouse/total time spent sniffing both mice). Data are presented as meanâÂ±âSEM. (<bold>e</bold>) and (<bold>h</bold>) Two-way repeated measures ANOVA. (<bold>b</bold>), (<bold>c</bold>), (<bold>f</bold>) and (<bold>i</bold>) One-way ANOVA. * <italic>p</italic>â&lt;â0.05, ** <italic>p</italic>â&lt;â0.01, *** <italic>p</italic>â&lt;â0.001</p></caption><graphic id="MO4" xlink:href="13041_2019_452_Fig4_HTML"></graphic></fig></p>
</sec>
</sec>
<sec id="Sec7">
<title>Discussion</title>
<p id="Par32">We showed that prenatally FLX-treated mice exhibited deficits in a working memory task and social novelty recognition paradigm via enhanced inhibitory synaptic activities in the L5 neurons of the mPFC resulting from enhanced 5-HT<sub>2A</sub>R signaling in FS PV neurons. More importantly, the acute inhibition of 5-HT<sub>2A</sub>R signaling in FLX-treated mice successfully reversed the observed behavioral deficits. Although 5-HT generally plays a critical role in mammalian neuronal development and behavior, the causal relationship between alterations in 5-HT homeostasis during pregnancy and adverse behavioral consequences in adulthood is poorly understood. Previously, several studies have attempted to address this question using both genetic deletion of SERT and SSRI administration in rodents. However, these studies suffered from inconsistent behavioral phenotypes, which were partially due to the use of different rodent strains and the type, dosage, and timing of administered SSRIs (see Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Table S1). In the present study, we adopted a treatment scheme similar to that of Noorlander et al. This treatment mimicked SSRI exposure before the 3rd trimester in humans, in which doctors recommend that pregnant women abstain from (or reduce the dose of) SSRIs during late pregnancy [<xref ref-type="bibr" rid="CR21">21</xref>]. In this paradigm, we consistently observed behavioral deficits in Y-maze spontaneous alternation tasks in prenatally FLX-treated mice without anxiety-related behaviors. More importantly, SSRI-treated mice exhibited normal sociability but impaired preference for social novelty in the three-chamber test (Fig. <xref ref-type="fig" rid="Fig1">1</xref>g-i), which is strikingly similar to the behaviors of mice lacking integrin Î²3, whose activities are linked to 5-HT transport and the pathophysiology of hyperserotonemia and autism [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>], as well as other mice lacking genes associated with autism [<xref ref-type="bibr" rid="CR42">42</xref>â<xref ref-type="bibr" rid="CR44">44</xref>].</p>
<p id="Par33">In contrast to previous studies by Ansorge et al. [<xref ref-type="bibr" rid="CR13">13</xref>] and Noorlander et al. [<xref ref-type="bibr" rid="CR21">21</xref>] we did not find an anxiety-like effect in adult mice in our experiments. This could be due to two reasons: First, Ansorge et al. [<xref ref-type="bibr" rid="CR13">13</xref>] employed postnatal treatment from P4-P21 and the difference in timeline of exposure to SSRI between the two protocols could have resulted in different developmental effects on different brain circuits. While the timing of our protocol was identical to that of Noorlander et al., [<xref ref-type="bibr" rid="CR21">21</xref>], the difference in dosage of FLX that was used (ours: 0.6âmg/kg/day; Noorlander et al.: 0.8âmg/kg/day) could have different effect on the maturation and/or modification of emotional brain circuits. Although the dose difference between two protocols seemed to be small, Noorlander et al. [<xref ref-type="bibr" rid="CR21">21</xref>] reported an increased mortality rate of offspring, which we did not observe in ours.</p>
<p id="Par34">We recorded spontaneous synaptic activities induced by local inhibitory and excitatory networks in single neurons within L5, a major output neuronal layer within the mPFC. A significant increase in the frequency of sIPSCs was observed in the mPFC of FLX-treated mice compared with that in SAL-treated mice (Fig. <xref ref-type="fig" rid="Fig2">2</xref>g-i), but the frequency of sEPSCs recorded in the same neurons was decreased (Fig. <xref ref-type="fig" rid="Fig2">2</xref>a-c). Because both sIPSCs and sEPSCs were recorded in the same L5 pyramidal neurons, these data indicate that the ratio of excitatory to inhibitory drive onto those neurons is abnormally low in FLX-treated mice. As increase in sIPSC frequency is caused by activity-dependent changes such as excitability, we next blocked APs in a slice with TTX and recorded mIPSCs in L5 pyramidal neurons. Intriguingly, significant differences in both frequency and amplitude of mIPSCs were not observed between FLX- and SAL-treated mice, indicating that the increased frequency of inhibitory currents observed in L5 mPFC neurons was due to activity-dependent GABAergic release. Because these excitatory neurons received inhibitory synaptic inputs from PV-positive FS interneurons, we measured the intrinsic excitability of L5 FS interneurons and observed a significant increase in intrinsic excitability without marked changes in channel properties or input resistance (Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Figure S3). We reasoned that the compensatory augmentation of specific 5-HT receptors could arise from prolonged exposure to 5-HT due to SSRI treatment and observed a concurrent increase in two 5-HT receptors, 5-HT<sub>1A</sub>R and <sub>2A</sub>R, using qPCR analysis. Because of the lack of suitable antibodies against 5-HT receptors for immunohistochemical analyses, we performed electrophysiological recordings and pharmacology to test the contribution of the increased abundance of specific 5-HT receptors in the PFC of FLX-treated mice. Surprisingly, increases in activity- and 5-HT-dependent changes in the excitability of FS interneurons were mediated by 5-HT<sub>2A</sub>Rs, but not 5-HT<sub>1A</sub>Rs (Fig. <xref ref-type="fig" rid="Fig3">3</xref>d-g and Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Figure S5). Although we do not clearly understand why 5-HT<sub>2A</sub>R signaling or expression was enhanced specifically in FS interneurons, Athilingam et al. recently showed that 5-HT treatment in FS interneurons resulted in the suppression of an inward-rectifying potassium conductance, which eventually lead to increased excitability of these interneurons via 5-HT<sub>2A</sub>Rs [<xref ref-type="bibr" rid="CR45">45</xref>], which might explain the excitability change in FS interneurons upon chronic SSRI treatment.</p>
<p id="Par35">Changes in sIPSC frequency or altered inhibitory drive relative to excitatory drive have been observed in other animal models of neurodevelopmental disorders in which working memory deficits have also been reported [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR46">46</xref>â<xref ref-type="bibr" rid="CR48">48</xref>]. Our findings support the hypothesis that environmental changes induced by a single drug during pregnancy elicits an imbalance in the inhibitory/excitatory drive onto major output neurons in the L5 microcircuits within the PFC and subsequently alters animal behavior through non-genetic, compensatory upregulation of unique classes of 5-HT receptors in specific neuronal types. However, the potential mechanism of this compensatory 5-HT-receptor upregulation in FS interneurons needs to be addressed. Furthermore, studies to determine whether L2/3 neurons in the mPFC or hippocampal neurons exhibit comparable changes in the intrinsic excitability of neurons and excitatory/inhibitory (E/I) imbalance in the network will be interesting. Our data also support the findings from recent optogenetic studies showing that acute modulation of the excitability of FS PV-positive interneurons within the mPFC elicits changes in network oscillation and the performance of cognitive flexibility behavior in mice [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. Therefore, measurements of network oscillations in FLX-treated mice during working memory or social novelty task using in vivo multi-electrode recordings will be exciting.</p>
<p id="Par36">The increased 5-HT<sub>2A</sub>R-mediated changes in the excitability of FS interneurons in FLX-treated mice prompted us to test whether the behavioral deficits of these mice were modulated by the application of a 5-HT<sub>2A</sub>R antagonist, such as MDL. The impairments of working memory and social novelty recognition were rescued by an in vivo treatment with MDL (Fig. <xref ref-type="fig" rid="Fig4">4</xref> b-i). It is intriguingly, because a MDL treatment rescues attentional performance deficits in phencyclidine-treated [<xref ref-type="bibr" rid="CR51">51</xref>] and NMDAR antagonist-treated [<xref ref-type="bibr" rid="CR52">52</xref>] rats. Because patients with schizophrenia, who usually exhibit working memory deficits, have very high 5-HT<sub>2A</sub>R occupancy in the frontal cortex [<xref ref-type="bibr" rid="CR53">53</xref>], the enhanced 5-HT<sub>2A</sub>R activity observed in our study may represent a general pathogenic mechanism of behavioral deficits in some mental disorders, and systemic administration of MDL might potentially restore synaptic and behavioral deficits in patients with disorders with similar etiologies.</p>
<p id="Par37">Taken together, our data revealed that altered prenatal 5-HT homeostasis results in mPFC-dependent behavioral deficits, and systemic modulation of the augmented 5-HT<sub>2A</sub>R sufficiently rescues these behavioral deficits. Furthermore, our findings may potentially provide new opportunities for the pharmacological treatment of patients who have been prenatally exposed to psychotropic medications during the prenatal period.</p>
</sec>
<sec id="Sec8">
<title>Materials and methods</title>
<sec id="Sec9">
<title>Animals</title>
<p id="Par38">Animals were housed in a specific pathogen-free facility maintained below 22âÂ°C and 55% humidity under a 12-h light-dark cycle (lights on at 0700âh) with food and water provided ad libitum [<xref ref-type="bibr" rid="CR54">54</xref>]. Timed pregnancy was achieved by breeding wild-type C57BL6J (The Jackson Laboratory) male mice with female mice.</p>
</sec>
<sec id="Sec10">
<title>Immunohistochemistry</title>
<p id="Par39">Mice were perfused with PBS, followed by 4% (<italic>w</italic>/<italic>v</italic>) paraformaldehyde in PBS (pHâ7.4). Brains were harvested and fixed with 4% paraformaldehyde overnight, transferred to 30% (w/v) sucrose in PBS, and then cryosectioned into 40âÎ¼m thick slices. For immunohistochemistry, brain slices were permeabilized with 0.2% Triton X-100 in PBS for 10âmin and transferred to blocking buffer (5% donkey serum, 2% BSA and 0.2% Triton X-100 in PBS) for 1âh at room temperature. Next, the sections were incubated with primary antibody for parvalbumin (1:1000 diluted in blocking buffer, PV-235, Swant) overnight at 4âÂ°C. The sections were subsequently incubated with appropriate secondary antibodies (1:500 diluted in blocking buffer, anti-streptavidin Alexa Fluor 488, anti-mouse Alexa Fluor 555; Invitrogen) for 2âh at room temperature. All sections were then stained with DAPI (1:5000 diluted with 0.2% Triton X-100 in PBS, Sigma-Aldrich) and mounted with Fluorsafe (Merck Millipore). Images were captured using an LSM 710 confocal microscope (Zeiss).</p>
</sec>
<sec id="Sec11">
<title>Electrophysiology</title>
<p id="Par40">L5 neurons were studied in acute coronal slices of the medial prefrontal cortex (mPFC) from male postnatal day 90â150 mice. After the mice were anesthetized by inhalation of 5% isoflurane, they were decapitated, and their brains were quickly removed and chilled in ice-cold, high-magnesium cutting solution containing the following components (in mM): 110 ChCl, 26 NaHCO<sub>3</sub>, 3.2 KCl, 0.5 CaCl<sub>2</sub>, 7 MgCl<sub>2</sub>, 1.25 NaH<sub>2</sub>PO<sub>4</sub>, 10 glucose, 2 sodium pyruvate, and 3 ascorbate [<xref ref-type="bibr" rid="CR55">55</xref>]. The pH was adjusted to 7.4 by saturation with carbogen (95% O<sub>2</sub> and 5% CO<sub>2</sub>), and the osmolality was approximately 300 mOsmol/L. The isolated brain was glued onto the stage of a vibrating blade Compresstome (VF-200, Precisionary), and 300âÎ¼m-thick slices were cut. The slices were incubated at 34âÂ°C for 30âmin in the same solution and thereafter maintained at room temperature. For experiments, we transferred a slice that recovered for at least one hour to a recording chamber superfused with artificial cerebrospinal fluid (aCSF) containing the following components (in mM): 124 NaCl, 26 NaHCO<sub>3</sub>, 3.2 KCl, 2.5 CaCl<sub>2</sub>, 1.3 MgCl<sub>2</sub>, 1.25 NaH<sub>2</sub>PO<sub>4</sub>, and 10 glucose. The aCSF was bubbled with 95% O<sub>2</sub> and 5% CO<sub>2</sub>. Whole-cell voltage- or current-clamp recordings (one cell per slice) were performed at 32âÂ±â1âÂ°C, and the rate of aCSF perfusion was maintained at 1â1.5âmlâmin<sup>ââ1</sup>. Recordings were performed in somata with a Multiclamp 700B amplifier. Patch pipettes for current-clamp mode were filled with internal solutions containing the following components (in mM): 115âK-gluconate, 20 KCl, 10 Na<sub>2</sub>-phosphocreatine, 10 HEPES, 2âMg-ATP, 0.3 NaGTP, and 0.1% biocytin. For voltage-clamp recordings, we used internal solutions containing the following components (in mM): 120 Cs-methane sulfonate, 10 CsCl, 10 TEA-Cl, 1 MgCl<sub>2</sub>, 10 HEPES, 0.1 EGTA, 0.4 Tris-GTP, 3âMg-ATP, and 5 Na<sub>2</sub>-phosphocreatine. We recorded series resistance throughout the experiments and excluded neurons with series resistance &gt;â20âMÎ© from data analysis. Membrane potential values were presented as recorded without correcting for liquid junction potentials. MDL10090, CNQX, APV, picrotoxin, and TTX were purchased from Tocris Bioscience. All other drugs were purchased from Sigma-Aldrich. Stock solutions of drugs were made by dissolving in deionized water or DMSO according to manufacturerâs specifications and were stored at ââ20âÂ°C. On the day of the experiment, one aliquot was thawed and used. The concentration of DMSO in solutions was maintained at 0.1%.</p>
</sec>
<sec id="Sec12">
<title>Behavioral assays and analyses</title>
<sec id="Sec13">
<title>Animals and fluoxetine treatment</title>
<p id="Par41">Male and female mice breeders were co-housed until pregnancy. The date when a plug was first noted was classified as ED0. From ED4 to ED19, pregnant females were housed individually and received daily i.p. injections of either FLX (0.6âmg/kg/day in a volume of 10âml/kg, Sigma) or equal volumes of SAL [<xref ref-type="bibr" rid="CR21">21</xref>]. Females used for injection were used only once to minimize the potential cross-generation effects of FLX administration. At postnatal day 21â23, offspring were weaned and housed with their same-sex littermates.</p>
</sec>
<sec id="Sec14">
<title>Behavioral assays</title>
<p id="Par42">For behavioral testing, we used adult males treated prenatally with either FLX or SAL. All animals were 12âweeks old at the time of testing. All tests except for the open-field test were conducted during the light phase. All behavioral apparatuses were cleaned with 70% ethanol and dried with tissue between each animal.</p>
</sec>
<sec id="Sec15">
<title>Open-field test</title>
<p id="Par43">The open-field test was conducted to measure general exploratory behavior. Mice were placed into the center of a Plexiglas cage (40.5âcmâÃâ40.5âcmâÃâ16âcm) for a 60-min test. Horizontal locomotion (i.e., distance traveled) was automatically recorded and analyzed by using Versamax software (AccuScan Instruments Inc).</p>
</sec>
<sec id="Sec16">
<title>Elevated zero maze</title>
<p id="Par44">Anxiety-related behavior was measured using the elevated zero maze (CSI-MZ-ZR, Cleversys), which consists of a circular runway subdivided into two closed and two open sections elevated 60âcm above the floor. Mice were initially introduced into one of the closed runways and were allowed to freely explore the apparatus for 10âmin. During the 10-min test, the percentage of time spent on the open arms and the number of transitions between two closed arms were scored using Topscan software (Cleversys).</p>
</sec>
<sec id="Sec17">
<title>Y-maze test</title>
<p id="Par45">To allow the mice to discriminate between the three arms of the Y-maze apparatus (San Diego Instruments), the sides of one arm of was lined with a pattern of black vertical bars on a white background with a black square at the end. The sides of another arm were lined with a pattern of solid circles with black triangles on a white background and a triangle marking the end. The remaining arm was not marked. The Y-maze test was conducted for 10âmin. The first minute was not coded and treated as the habituation period. Subsequently, the entries into each arm were recoded. The spontaneous alternation index was calculated as the number of non-repeating triplets (for example, if each arm was labeled âAâ, âBâ or âCâ, âABCACââ=â2) divided by the total number of possible non-repeating triplets (total number of entries into each arm - 2).</p>
</sec>
<sec id="Sec18">
<title>Novel object recognition test</title>
<p id="Par46">The novel object recognition test was conducted in the open-field apparatus, which was subdivided equally into two arenas with a red plastic divider. For training, two identical objects constructed out of Lego blocks were placed at either end of the arena. Mice were allowed to explore and familiarize themselves with the two objects for 10âmins. They were returned to their cages for 20âmin while the arena and the objects were cleaned to remove any odor cues. Afterwards, a test of short-term memory was conducted by placing the familiar object and a novel object that differed in shape, color, and size at either end of the arena. The duration of sniffing and bouts of sniffing were manually recorded using Topscan software (CleverSys).</p>
</sec>
<sec id="Sec19">
<title>Social cognition tests</title>
<p id="Par47">Social preference and social recognition were tested using a three-chamber apparatus (CSI-SO-PP, CleverSys). The entire test consists of three consecutive 10âmin blocks. For the first block, mice were habituated to the entire apparatus and two empty wire pencil holders placed at opposite corners. For the second block, one juvenile male mouse (social stimulus) was placed in one holder, and a dummy object (non-social stimulus) was placed in the other holder to test for social preference. For the last block, the juvenile mouse remained in one holder (familiar), but the dummy object was replaced by a novel juvenile male mouse (novel) to test for social discrimination.</p>
</sec>
</sec>
<sec id="Sec20">
<title>Golgi staining and tracing</title>
<p id="Par48">Mice were perfused with PBS and placed in impregnation solution (FD Rapid Golgi-Stain Kit, FD Neurotech) for one week. 100âÎ¼m sections were cut on a cryostat, processed using the kitâs standard staining procedure and images were taken with the confocal microscope. Z-stack images were traced and analyzed with the Simple Neurite Tracer plugin for ImageJ.</p>
</sec>
<sec id="Sec21">
<title>Gene expression study</title>
<p id="Par49">Total RNA was extracted from punched samples of the mPFC using an RNeasy kit (Qiagen) followed by cDNA synthesis using a Quantitect Reverse Transcription kit (Qiagen). Real-time polymerase chain reaction (PCR) was performed on three independent sets of templates using iQ SYBR Green Supermix (Bio-Rad). The amplification mixture consisted of 1âÎ¼M primers, 10âÎ¼l of iQ SYBR Green Supermix (Bio-Rad), and 100âng of template DNA in a total volume of 20âÎ¼l. Cycling parameters were 95âÂ°C for 15âs, 57âÂ°C for 1âmin and 72âÂ°C for 40âcycles using a CFX96 real-time PCR detection system (Bio-Rad). For each assay, PCR was performed after melting curve analysis. To reduce variability, we ran each sample in duplicate and included control qPCR reactions without the template in each run.</p>
<p id="Par50">For microarray analyses, we normalized all microarray data using RMA method provided by the affy package [<xref ref-type="bibr" rid="CR56">56</xref>] and analyzed differentially expressed genes using the limma package [<xref ref-type="bibr" rid="CR57">57</xref>]. For gene-probe mapping information and GO term annotation, we used the EnsEMBL database (version 90).</p>
</sec>
<sec id="Sec22">
<title>Statistical analyses</title>
<p id="Par51">Data were analyzed and plotted using GraphPad Prism (GraphPad Software) and are presented as the means Â± SEM with symbols representing individual subjects. Data from the open-field test data were analyzed using two-way repeated-measures ANOVA, followed by Tukeyâs post hoc test. The rest of the data were analyzed using the Mann-Whitney test, Wilcoxon Signed rank test, and unpaired t-test. <italic>P</italic>â&lt;â0.05 was considered statistically significant. In addition, extreme values were subjected to Grubbâs test for outliers (<ext-link ext-link-type="uri" xlink:href="http://graphpad.com/quickcalcs/Grubbs1.cfm">http://graphpad.com/quickcalcs/Grubbs1.cfm</ext-link>) and excluded from the analysis.</p>
</sec>
</sec>
<sec sec-type="supplementary-material">
<title>Additional file</title>
<sec id="Sec23">
<p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="13041_2019_452_MOESM1_ESM.pdf"><label>Additional file 1:</label><caption><p><bold>Figure S1.</bold> Prenatal FLX treatment does not induce other behavioral deficits. <bold>Figure S2.</bold> The prenatal FLX treatment does not change the morphology or spine density of L5 PrL neurons. <bold>Figure S3.</bold> Passive membrane properties of FS interneurons in the PrL of SAL- and FLX- treated mice. <bold>Figure S4.</bold> Expression of the mRNAs encoding serotonergic receptors and transporters and effects of the 5-HT treatment on IPSC frequency and amplitude. <bold>Figure S5.</bold> Effect of 5-HT1AR antagonists on FS interneurons in the PrL of SAL- and FLX-treated mice. <bold>Figure S6.</bold> Effects of the 5-HT treatment on pyramidal neurons in the PrL of SAL- and FLX-treated mice. <bold>Table S1.</bold> Summary of studies investigating the effects of perinatal serotonin reuptake inhibitors (SSRI) on adult male mice. <bold>Table S2.</bold> Intrinsic properties of fast-spiking interneurons of SAL and FLX treated mice before and after 5HT-treatment. <bold>Table S3.</bold> Statistical analysis conducted for each behavioral test. (PDF 1403 kb)</p></caption></media></supplementary-material>
</p>
</sec>
</sec>
</body>
<back>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>5-HT (serotonin)</term>
<def>
<p id="Par2">5-hydrotryptamine</p>
</def>
</def-item>
<def-item>
<term>5-HT<sub>2A</sub>R</term>
<def>
<p id="Par3">5-HT 2A receptor</p>
</def>
</def-item>
<def-item>
<term>APV</term>
<def>
<p id="Par4">(2R)-amino-5-phosphonopentanoic acid</p>
</def>
</def-item>
<def-item>
<term>FLX</term>
<def>
<p id="Par5">Fluoxetine</p>
</def>
</def-item>
<def-item>
<term>FS</term>
<def>
<p id="Par6">Fast-spiking</p>
</def>
</def-item>
<def-item>
<term>mEPSCs</term>
<def>
<p id="Par7">Miniature excitatory postsynaptic currents</p>
</def>
</def-item>
<def-item>
<term>mIPSCs</term>
<def>
<p id="Par8">Miniature inhibitory postsynaptic currents</p>
</def>
</def-item>
<def-item>
<term>mPFC</term>
<def>
<p id="Par9">Medial prefrontal cortex</p>
</def>
</def-item>
<def-item>
<term>NMDA</term>
<def>
<p id="Par10"><italic>N</italic>-methyl-<italic>D</italic>-aspartate</p>
</def>
</def-item>
<def-item>
<term>PrL</term>
<def>
<p id="Par11">prelimbic area</p>
</def>
</def-item>
<def-item>
<term>PV</term>
<def>
<p id="Par12">Parvalbumin</p>
</def>
</def-item>
<def-item>
<term>SAL</term>
<def>
<p id="Par13">Saline</p>
</def>
</def-item>
<def-item>
<term>sEPSCs</term>
<def>
<p id="Par14">Spontaneous excitatory postsynaptic currents</p>
</def>
</def-item>
<def-item>
<term>SERT</term>
<def>
<p id="Par15">Serotonin transporter</p>
</def>
</def-item>
<def-item>
<term>sIPSCs</term>
<def>
<p id="Par16">Spontaneous inhibitory postsynaptic currents</p>
</def>
</def-item>
<def-item>
<term>SSRI</term>
<def>
<p id="Par17">Selective serotonin reuptake inhibitor</p>
</def>
</def-item>
<def-item>
<term>TTX</term>
<def>
<p id="Par18">Tetrodotoxin</p>
</def>
</def-item>
</def-list>
</glossary>
<ack>
<p>We would like to thank Dr. Ann-Marie Chacko and her team for the Duke-NUS Laboratory for Translational and Molecular Imaging (LTMI) for their helpful discussions and generously sharing reagents. We thank Drs. Justin Lee, Chul-Hoon Kim, and Eddy Leman for their critical comments on the manuscript.</p>
<sec id="FPar1">
<title>Funding</title>
<p id="Par52">This work was supported by Singapore Ministry of Education (MOE) Academic Research Fund (MOE2012-T2â1-021, MOE2014-T2â2-071), National Medical Research Council Individual Research Grant (NMRC/CBRG/0075/2014 and NMRC/OFIRG/0050/2017) and Translational Clinical Research Programme in Parkinsonâs Disease (NMRC/TCR/013-NNI/2014), A*Star Translational Collaborative Research Partnership Grant (TCRP, 13/1/96/688), National Research Foundation (NRF-CRP17â2017-04), Duke-NUS Signature Research Program Block Grant (all to H.S.J.), and a Khoo Postdoctoral Fellowship Award (Duke-NUS-KPFA/2017/0016, to S. T.). T.K. was supported by Basic Science Research Program via the National Research Foundation of Korea (NRF-2016R1C1B2009302) and the UNIST block grant (1.170009.01).</p>
</sec>
<sec id="FPar2" sec-type="data-availability">
<title>Availability of data and materials</title>
<p id="Par53">Please contact author for data requests.</p>
</sec>
</ack>
<notes notes-type="author-contribution">
<title>Authorsâ contributions</title>
<p>WY designed and performed most of electrophysiological recordings; YW, YHL, and ST performed behavioral assays and immunohistochemistry; YX performed electrophysiological recordings and immunohistochemistry; AT and HG performed behavioral assays and analyzed data; HL and TK performed qPCR and genechip analyses; HSJ supervised the project. HSJ contributed to ideas, designed, and wrote the manuscript.</p>
</notes>
<notes notes-type="COI-statement">
<sec id="FPar3">
<title>Ethics approval</title>
<p>All animal procedures were approved by the Institutional Animal Care and Use Committee of Duke-NUS Medical School and SingHealth (IACUC #2010/SHS/590 and #2014/SHS/999).</p>
</sec>
<sec id="FPar4">
<title>Consent for publication</title>
<p>All authors agreed to its submission to the <italic>Molecular Brain</italic> and, if accepted, to its publication in this journal.</p>
</sec>
<sec id="FPar5">
<title>Competing interests</title>
<p>The authors declare that they have no competing interests.</p>
</sec>
<sec id="FPar6">
<title>Publisherâs Note</title>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</sec>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oberlander</surname>
<given-names>TF</given-names>
</name>
<name>
<surname>Warburton</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Misri</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Aghajanian</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hertzman</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data</article-title>
<source/>Arch Gen Psychiatry
          <year>2006</year>
<volume>63</volume>
<issue>8</issue>
<fpage>898</fpage>
<lpage>906</lpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.63.8.898</pub-id>
<pub-id pub-id-type="pmid">16894066</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bennett</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Einarson</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Taddio</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Koren</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Einarson</surname>
<given-names>TR</given-names>
</name>
</person-group>
<article-title>Prevalence of depression during pregnancy: systematic review</article-title>
<source/>Obstet Gynecol
          <year>2004</year>
<volume>103</volume>
<issue>4</issue>
<fpage>698</fpage>
<lpage>709</lpage>
<pub-id pub-id-type="doi">10.1097/01.AOG.0000116689.75396.5f</pub-id>
<pub-id pub-id-type="pmid">15051562</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morales</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Slattery</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kurz</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>Antidepressant use during pregnancy and risk of autism spectrum disorder and attention deficit hyperactivity disorder: systematic review of observational studies and methodological considerations</article-title>
<source/>BMC Med
          <year>2018</year>
<volume>16</volume>
<issue>1</issue>
<fpage>6</fpage>
<pub-id pub-id-type="doi">10.1186/s12916-017-0993-3</pub-id>
<pub-id pub-id-type="pmid">29332605</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stahl</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects</article-title>
<source/>J Affect Disord
          <year>1998</year>
<volume>51</volume>
<issue>3</issue>
<fpage>215</fpage>
<lpage>235</lpage>
<pub-id pub-id-type="doi">10.1016/S0165-0327(98)00221-3</pub-id>
<pub-id pub-id-type="pmid">10333979</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krishnan</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Nestler</surname>
<given-names>EJ</given-names>
</name>
</person-group>
<article-title>The molecular neurobiology of depression</article-title>
<source/>Nature.
          <year>2008</year>
<volume>455</volume>
<issue>7215</issue>
<fpage>894</fpage>
<lpage>902</lpage>
<pub-id pub-id-type="doi">10.1038/nature07455</pub-id>
<pub-id pub-id-type="pmid">18923511</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Willner</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Antidepressants and serotonergic neurotransmission: an integrative review</article-title>
<source/>Psychopharmacology
          <year>1985</year>
<volume>85</volume>
<issue>4</issue>
<fpage>387</fpage>
<lpage>404</lpage>
<pub-id pub-id-type="doi">10.1007/BF00429653</pub-id>
<pub-id pub-id-type="pmid">2410942</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kirsch</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Deacon</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Huedo-Medina</surname>
<given-names>TB</given-names>
</name>
<name>
<surname>Scoboria</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>BT</given-names>
</name>
</person-group>
<article-title>Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration</article-title>
<source/>PLoS Med
          <year>2008</year>
<volume>5</volume>
<issue>2</issue>
<fpage>e45</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pmed.0050045</pub-id>
<pub-id pub-id-type="pmid">18303940</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turner</surname>
<given-names>EH</given-names>
</name>
<name>
<surname>Matthews</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Linardatos</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Tell</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Rosenthal</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Selective publication of antidepressant trials and its influence on apparent efficacy</article-title>
<source/>N Engl J Med
          <year>2008</year>
<volume>358</volume>
<issue>3</issue>
<fpage>252</fpage>
<lpage>260</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMsa065779</pub-id>
<pub-id pub-id-type="pmid">18199864</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaplan</surname>
<given-names>YC</given-names>
</name>
<name>
<surname>Keskin-Arslan</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Acar</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sozmen</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Prenatal selective serotonin reuptake inhibitor use and the risk of autism spectrum disorder in children: a systematic review and meta-analysis</article-title>
<source/>Reprod Toxicol
          <year>2016</year>
<volume>66</volume>
<fpage>31</fpage>
<lpage>43</lpage>
<pub-id pub-id-type="doi">10.1016/j.reprotox.2016.09.013</pub-id>
<pub-id pub-id-type="pmid">27667009</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hiemke</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hartter</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Pharmacokinetics of selective serotonin reuptake inhibitors</article-title>
<source/>Pharmacol Ther
          <year>2000</year>
<volume>85</volume>
<issue>1</issue>
<fpage>11</fpage>
<lpage>28</lpage>
<pub-id pub-id-type="doi">10.1016/S0163-7258(99)00048-0</pub-id>
<pub-id pub-id-type="pmid">10674711</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clements</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Castro</surname>
<given-names>VM</given-names>
</name>
<name>
<surname>Blumenthal</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Rosenfield</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>SN</given-names>
</name>
<name>
<surname>Fava</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Prenatal antidepressant exposure is associated with risk for attention-deficit hyperactivity disorder but not autism spectrum disorder in a large health system</article-title>
<source/>Mol Psychiatry
          <year>2015</year>
<volume>20</volume>
<issue>6</issue>
<fpage>727</fpage>
<lpage>734</lpage>
<pub-id pub-id-type="doi">10.1038/mp.2014.90</pub-id>
<pub-id pub-id-type="pmid">25155880</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huybrechts</surname>
<given-names>KF</given-names>
</name>
<name>
<surname>Sanghani</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Avorn</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Urato</surname>
<given-names>AC</given-names>
</name>
</person-group>
<article-title>Preterm birth and antidepressant medication use during pregnancy: a systematic review and meta-analysis</article-title>
<source/>PLoS One
          <year>2014</year>
<volume>9</volume>
<issue>3</issue>
<fpage>e92778</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0092778</pub-id>
<pub-id pub-id-type="pmid">24671232</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ansorge</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lira</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gingrich</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice</article-title>
<source/>Science.
          <year>2004</year>
<volume>306</volume>
<issue>5697</issue>
<fpage>879</fpage>
<lpage>881</lpage>
<pub-id pub-id-type="doi">10.1126/science.1101678</pub-id>
<pub-id pub-id-type="pmid">15514160</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gross</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zhuang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Stark</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ramboz</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Oosting</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kirby</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult</article-title>
<source/>Nature.
          <year>2002</year>
<volume>416</volume>
<issue>6879</issue>
<fpage>396</fpage>
<lpage>400</lpage>
<pub-id pub-id-type="doi">10.1038/416396a</pub-id>
<pub-id pub-id-type="pmid">11919622</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Homberg</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>A mouse model to address unresolved antidepressant issues</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2011</year>
<volume>108</volume>
<issue>9</issue>
<fpage>3463</fpage>
<lpage>3464</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1100757108</pub-id>
<pub-id pub-id-type="pmid">21368215</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cases</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Seif</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Grimsby</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gaspar</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Pournin</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA</article-title>
<source/>Science.
          <year>1995</year>
<volume>268</volume>
<issue>5218</issue>
<fpage>1763</fpage>
<lpage>1766</lpage>
<pub-id pub-id-type="doi">10.1126/science.7792602</pub-id>
<pub-id pub-id-type="pmid">7792602</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holmes</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Lesch</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>Crawley</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>DL</given-names>
</name>
</person-group>
<article-title>Mice lacking the serotonin transporter exhibit 5-HT (1A) receptor-mediated abnormalities in tests for anxiety-like behavior</article-title>
<source/>Neuropsychopharmacology.
          <year>2003</year>
<volume>28</volume>
<issue>12</issue>
<fpage>2077</fpage>
<lpage>2088</lpage>
<pub-id pub-id-type="doi">10.1038/sj.npp.1300266</pub-id>
<pub-id pub-id-type="pmid">12968128</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jennings</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Loder</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Sheward</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Pei</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Deacon</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Benson</surname>
<given-names>MA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Increased expression of the 5-HT transporter confers a low-anxiety phenotype linked to decreased 5-HT transmission</article-title>
<source/>J Neurosci
          <year>2006</year>
<volume>26</volume>
<issue>35</issue>
<fpage>8955</fpage>
<lpage>8964</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.5356-05.2006</pub-id>
<pub-id pub-id-type="pmid">16943551</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simpson</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Weaver</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>de Villers-Sidani</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Pang</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Perinatal antidepressant exposure alters cortical network function in rodents</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2011</year>
<volume>108</volume>
<issue>45</issue>
<fpage>18465</fpage>
<lpage>18470</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1109353108</pub-id>
<pub-id pub-id-type="pmid">22025710</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kehne</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Baron</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Carr</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Chaney</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Elands</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Feldman</surname>
<given-names>DJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile</article-title>
<source/>J Pharmacol Exp Ther
          <year>1996</year>
<volume>277</volume>
<issue>2</issue>
<fpage>968</fpage>
<lpage>981</lpage>
<pub-id pub-id-type="pmid">8627580</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Noorlander</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Ververs</surname>
<given-names>FF</given-names>
</name>
<name>
<surname>Nikkels</surname>
<given-names>PG</given-names>
</name>
<name>
<surname>van Echteld</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Visser</surname>
<given-names>GH</given-names>
</name>
<name>
<surname>Smidt</surname>
<given-names>MP</given-names>
</name>
</person-group>
<article-title>Modulation of serotonin transporter function during fetal development causes dilated heart cardiomyopathy and lifelong behavioral abnormalities</article-title>
<source/>PLoS One
          <year>2008</year>
<volume>3</volume>
<issue>7</issue>
<fpage>e2782</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0002782</pub-id>
<pub-id pub-id-type="pmid">18716672</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chadman</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Crawley</surname>
<given-names>JN</given-names>
</name>
</person-group>
<article-title>Criteria for validating mouse models of psychiatric diseases</article-title>
<source/>Am J Med Genet B Neuropsychiatr Genet
          <year>2009</year>
<volume>150B</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>11</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.b.30777</pub-id>
<pub-id pub-id-type="pmid">18484083</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Belforte</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Zsiros</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Sklar</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes</article-title>
<source/>Nat Neurosci
          <year>2010</year>
<volume>13</volume>
<issue>1</issue>
<fpage>76</fpage>
<lpage>83</lpage>
<pub-id pub-id-type="doi">10.1038/nn.2447</pub-id>
<pub-id pub-id-type="pmid">19915563</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Albert</surname>
<given-names>PR</given-names>
</name>
</person-group>
<article-title>Transcriptional regulation of the 5-HT1A receptor: implications for mental illness</article-title>
<source/>Philos Trans R Soc Lond Ser B Biol Sci
          <year>2012</year>
<volume>367</volume>
<issue>1601</issue>
<fpage>2402</fpage>
<lpage>2415</lpage>
<pub-id pub-id-type="doi">10.1098/rstb.2011.0376</pub-id>
<pub-id pub-id-type="pmid">22826341</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Silverman</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lord</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Crawley</surname>
<given-names>JN</given-names>
</name>
</person-group>
<article-title>Behavioural phenotyping assays for mouse models of autism</article-title>
<source/>Nat Rev Neurosci
          <year>2010</year>
<volume>11</volume>
<issue>7</issue>
<fpage>490</fpage>
<lpage>502</lpage>
<pub-id pub-id-type="doi">10.1038/nrn2851</pub-id>
<pub-id pub-id-type="pmid">20559336</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yen</surname>
<given-names>YC</given-names>
</name>
<name>
<surname>Anderzhanova</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bunck</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schuller</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Landgraf</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wotjak</surname>
<given-names>CT</given-names>
</name>
</person-group>
<article-title>Co-segregation of hyperactivity, active coping styles, and cognitive dysfunction in mice selectively bred for low levels of anxiety</article-title>
<source/>Front Behav Neurosci
          <year>2013</year>
<volume>7</volume>
<fpage>103</fpage>
<pub-id pub-id-type="doi">10.3389/fnbeh.2013.00103</pub-id>
<pub-id pub-id-type="pmid">23966915</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ko</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Neuroanatomical substrates of rodent social behavior: the medial prefrontal cortex and its projection patterns</article-title>
<source/>Front Neural Circuits
          <year>2017</year>
<volume>11</volume>
<fpage>41</fpage>
<pub-id pub-id-type="doi">10.3389/fncir.2017.00041</pub-id>
<pub-id pub-id-type="pmid">28659766</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anderson</surname>
<given-names>DJ</given-names>
</name>
</person-group>
<article-title>Circuit modules linking internal states and social behaviour in flies and mice</article-title>
<source/>Nat Rev Neurosci
          <year>2016</year>
<volume>17</volume>
<issue>11</issue>
<fpage>692</fpage>
<lpage>704</lpage>
<pub-id pub-id-type="doi">10.1038/nrn.2016.125</pub-id>
<pub-id pub-id-type="pmid">27752072</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krueger</surname>
<given-names>DD</given-names>
</name>
<name>
<surname>Osterweil</surname>
<given-names>EK</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Tye</surname>
<given-names>LD</given-names>
</name>
<name>
<surname>Bear</surname>
<given-names>MF</given-names>
</name>
</person-group>
<article-title>Cognitive dysfunction and prefrontal synaptic abnormalities in a mouse model of fragile X syndrome</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2011</year>
<volume>108</volume>
<issue>6</issue>
<fpage>2587</fpage>
<lpage>2592</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1013855108</pub-id>
<pub-id pub-id-type="pmid">21262808</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuan</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Husain</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Regulation of brain-derived neurotrophic factor exocytosis and gamma-aminobutyric Acidergic interneuron synapse by the schizophrenia susceptibility gene Dysbindin-1</article-title>
<source/>Biol Psychiatry
          <year>2016</year>
<volume>80</volume>
<issue>4</issue>
<fpage>312</fpage>
<lpage>322</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2015.08.019</pub-id>
<pub-id pub-id-type="pmid">26386481</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jakab</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Goldman-Rakic</surname>
<given-names>PS</given-names>
</name>
</person-group>
<article-title>5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>1998</year>
<volume>95</volume>
<issue>2</issue>
<fpage>735</fpage>
<lpage>740</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.95.2.735</pub-id>
<pub-id pub-id-type="pmid">9435262</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jakab</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Goldman-Rakic</surname>
<given-names>PS</given-names>
</name>
</person-group>
<article-title>Segregation of serotonin 5-HT2A and 5-HT3 receptors in inhibitory circuits of the primate cerebral cortex</article-title>
<source/>J Comp Neurol
          <year>2000</year>
<volume>417</volume>
<issue>3</issue>
<fpage>337</fpage>
<lpage>348</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1096-9861(20000214)417:3&lt;337::AID-CNE7&gt;3.0.CO;2-O</pub-id>
<pub-id pub-id-type="pmid">10683608</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smiley</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Goldman-Rakic</surname>
<given-names>PS</given-names>
</name>
</person-group>
<article-title>Serotonergic axons in monkey prefrontal cerebral cortex synapse predominantly on interneurons as demonstrated by serial section electron microscopy</article-title>
<source/>J Comp Neurol
          <year>1996</year>
<volume>367</volume>
<issue>3</issue>
<fpage>431</fpage>
<lpage>443</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1096-9861(19960408)367:3&lt;431::AID-CNE8&gt;3.0.CO;2-6</pub-id>
<pub-id pub-id-type="pmid">8698902</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nautiyal</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Hen</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Serotonin receptors in depression: from A to B</article-title>
<source/>F1000Res
          <year>2017</year>
<volume>6</volume>
<fpage>123</fpage>
<pub-id pub-id-type="doi">10.12688/f1000research.9736.1</pub-id>
<pub-id pub-id-type="pmid">28232871</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Hablitz</surname>
<given-names>JJ</given-names>
</name>
</person-group>
<article-title>Activation of serotonin receptors modulates synaptic transmission in rat cerebral cortex</article-title>
<source/>J Neurophysiol
          <year>1999</year>
<volume>82</volume>
<issue>6</issue>
<fpage>2989</fpage>
<lpage>2999</lpage>
<pub-id pub-id-type="doi">10.1152/jn.1999.82.6.2989</pub-id>
<pub-id pub-id-type="pmid">10601434</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weber</surname>
<given-names>ET</given-names>
</name>
<name>
<surname>Andrade</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Htr2a gene and 5-HT (2A) receptor expression in the cerebral cortex studied using genetically modified mice</article-title>
<source/>Front Neurosci
          <year>2010</year>
<volume>4</volume>
<fpage>36</fpage>
<pub-id pub-id-type="pmid">20802802</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McBain</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Fisahn</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Interneurons unbound</article-title>
<source/>Nat Rev Neurosci
          <year>2001</year>
<volume>2</volume>
<issue>1</issue>
<fpage>11</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="doi">10.1038/35049047</pub-id>
<pub-id pub-id-type="pmid">11253355</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tamas</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Buhl</surname>
<given-names>EH</given-names>
</name>
<name>
<surname>Lorincz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Somogyi</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Proximally targeted GABAergic synapses and gap junctions synchronize cortical interneurons</article-title>
<source/>Nat Neurosci
          <year>2000</year>
<volume>3</volume>
<issue>4</issue>
<fpage>366</fpage>
<lpage>371</lpage>
<pub-id pub-id-type="doi">10.1038/73936</pub-id>
<pub-id pub-id-type="pmid">10725926</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhong</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>Differential regulation of the excitability of prefrontal cortical fast-spiking interneurons and pyramidal neurons by serotonin and fluoxetine</article-title>
<source/>PLoS One
          <year>2011</year>
<volume>6</volume>
<issue>2</issue>
<fpage>e16970</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0016970</pub-id>
<pub-id pub-id-type="pmid">21383986</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carter</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Crawley</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Carneiro</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Veenstra-VanderWeele</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Absence of preference for social novelty and increased grooming in integrin beta3 knockout mice: initial studies and future directions</article-title>
<source/>Autism Res
          <year>2011</year>
<volume>4</volume>
<issue>1</issue>
<fpage>57</fpage>
<lpage>67</lpage>
<pub-id pub-id-type="doi">10.1002/aur.180</pub-id>
<pub-id pub-id-type="pmid">21254450</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carneiro</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Cook</surname>
<given-names>EH</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Blakely</surname>
<given-names>RD</given-names>
</name>
</person-group>
<article-title>Interactions between integrin alphaIIbbeta3 and the serotonin transporter regulate serotonin transport and platelet aggregation in mice and humans</article-title>
<source/>J Clin Invest
          <year>2008</year>
<volume>118</volume>
<issue>4</issue>
<fpage>1544</fpage>
<lpage>1552</lpage>
<pub-id pub-id-type="doi">10.1172/JCI33374</pub-id>
<pub-id pub-id-type="pmid">18317590</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Molina</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Carmona-Mora</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Chrast</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Krall</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Canales</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Lupski</surname>
<given-names>JR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Abnormal social behaviors and altered gene expression rates in a mouse model for Potocki-Lupski syndrome</article-title>
<source/>Hum Mol Genet
          <year>2008</year>
<volume>17</volume>
<issue>16</issue>
<fpage>2486</fpage>
<lpage>2495</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddn148</pub-id>
<pub-id pub-id-type="pmid">18469339</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jin</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>HX</given-names>
</name>
<name>
<surname>Hirai</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Torashima</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nagai</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Lopatina</surname>
<given-names>O</given-names>
</name>
<etal></etal>
</person-group>
<article-title>CD38 is critical for social behaviour by regulating oxytocin secretion</article-title>
<source/>Nature.
          <year>2007</year>
<volume>446</volume>
<issue>7131</issue>
<fpage>41</fpage>
<lpage>45</lpage>
<pub-id pub-id-type="doi">10.1038/nature05526</pub-id>
<pub-id pub-id-type="pmid">17287729</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferguson</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Hearn</surname>
<given-names>EF</given-names>
</name>
<name>
<surname>Matzuk</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Insel</surname>
<given-names>TR</given-names>
</name>
<name>
<surname>Winslow</surname>
<given-names>JT</given-names>
</name>
</person-group>
<article-title>Social amnesia in mice lacking the oxytocin gene</article-title>
<source/>Nat Genet
          <year>2000</year>
<volume>25</volume>
<issue>3</issue>
<fpage>284</fpage>
<lpage>288</lpage>
<pub-id pub-id-type="doi">10.1038/77040</pub-id>
<pub-id pub-id-type="pmid">10888874</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Athilingam</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Ben-Shalom</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Keeshen</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Sohal</surname>
<given-names>VS</given-names>
</name>
<name>
<surname>Bender</surname>
<given-names>KJ</given-names>
</name>
</person-group>
<article-title>Serotonin enhances excitability and gamma frequency temporal integration in mouse prefrontal fast-spiking interneurons</article-title>
<source/>Elife.
          <year>2017</year>
<volume>6</volume>
<fpage>e31991</fpage>
<pub-id pub-id-type="doi">10.7554/eLife.31991</pub-id>
<pub-id pub-id-type="pmid">29206101</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holtzman</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Santucci</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kilbridge</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chua-Couzens</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Fontana</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Daniels</surname>
<given-names>SE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>1996</year>
<volume>93</volume>
<issue>23</issue>
<fpage>13333</fpage>
<lpage>13338</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.93.23.13333</pub-id>
<pub-id pub-id-type="pmid">8917591</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haberecht</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Menon</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Warsofsky</surname>
<given-names>IS</given-names>
</name>
<name>
<surname>White</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Dyer-Friedman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Glover</surname>
<given-names>GH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Functional neuroanatomy of visuo-spatial working memory in Turner syndrome</article-title>
<source/>Hum Brain Mapp
          <year>2001</year>
<volume>14</volume>
<issue>2</issue>
<fpage>96</fpage>
<lpage>107</lpage>
<pub-id pub-id-type="doi">10.1002/hbm.1044</pub-id>
<pub-id pub-id-type="pmid">11500993</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tabuchi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Blundell</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Etherton</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Hammer</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Powell</surname>
<given-names>CM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A neuroligin-3 mutation implicated in autism increases inhibitory synaptic transmission in mice</article-title>
<source/>Science.
          <year>2007</year>
<volume>318</volume>
<issue>5847</issue>
<fpage>71</fpage>
<lpage>76</lpage>
<pub-id pub-id-type="doi">10.1126/science.1146221</pub-id>
<pub-id pub-id-type="pmid">17823315</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sohal</surname>
<given-names>VS</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Yizhar</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Deisseroth</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Parvalbumin neurons and gamma rhythms enhance cortical circuit performance</article-title>
<source/>Nature.
          <year>2009</year>
<volume>459</volume>
<issue>7247</issue>
<fpage>698</fpage>
<lpage>702</lpage>
<pub-id pub-id-type="doi">10.1038/nature07991</pub-id>
<pub-id pub-id-type="pmid">19396159</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cardin</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Carlen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Meletis</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Knoblich</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Deisseroth</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Driving fast-spiking cells induces gamma rhythm and controls sensory responses</article-title>
<source/>Nature.
          <year>2009</year>
<volume>459</volume>
<issue>7247</issue>
<fpage>663</fpage>
<lpage>667</lpage>
<pub-id pub-id-type="doi">10.1038/nature08002</pub-id>
<pub-id pub-id-type="pmid">19396156</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poyurovsky</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Koren</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Gonopolsky</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Schneidman</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fuchs</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Weizman</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study</article-title>
<source/>Eur Neuropsychopharmacol
          <year>2003</year>
<volume>13</volume>
<issue>2</issue>
<fpage>123</fpage>
<lpage>128</lpage>
<pub-id pub-id-type="doi">10.1016/S0924-977X(02)00155-4</pub-id>
<pub-id pub-id-type="pmid">12650957</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mirjana</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Baviera</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Invernizzi</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Balducci</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>The serotonin 5-HT2A receptors antagonist M100907 prevents impairment in attentional performance by NMDA receptor blockade in the rat prefrontal cortex</article-title>
<source/>Neuropsychopharmacology.
          <year>2004</year>
<volume>29</volume>
<issue>9</issue>
<fpage>1637</fpage>
<lpage>1647</lpage>
<pub-id pub-id-type="doi">10.1038/sj.npp.1300479</pub-id>
<pub-id pub-id-type="pmid">15127084</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Talvik-Lotfi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nyberg</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nordstrom</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Halldin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Brunner</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>High 5HT2A receptor occupancy in M100907-treated schizophrenic patients</article-title>
<source/>Psychopharmacology
          <year>2000</year>
<volume>148</volume>
<issue>4</issue>
<fpage>400</fpage>
<lpage>403</lpage>
<pub-id pub-id-type="doi">10.1007/s002130050069</pub-id>
<pub-id pub-id-type="pmid">10928313</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>AY</given-names>
</name>
<name>
<surname>Low</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Je</surname>
<given-names>HS</given-names>
</name>
</person-group>
<article-title>Maternal separation does not produce a significant behavioral change in mice</article-title>
<source/>Exp Neurobiol
          <year>2017</year>
<volume>26</volume>
<issue>6</issue>
<fpage>390</fpage>
<lpage>398</lpage>
<pub-id pub-id-type="doi">10.5607/en.2017.26.6.390</pub-id>
<pub-id pub-id-type="pmid">29302206</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>WK</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>SH</given-names>
</name>
</person-group>
<article-title>Target cell-specific involvement of presynaptic mitochondria in post-tetanic potentiation at hippocampal mossy fiber synapses</article-title>
<source/>J Neurosci
          <year>2007</year>
<volume>27</volume>
<issue>50</issue>
<fpage>13603</fpage>
<lpage>13613</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.3985-07.2007</pub-id>
<pub-id pub-id-type="pmid">18077672</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gautier</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cope</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bolstad</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Irizarry</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Affy--analysis of Affymetrix GeneChip data at the probe level</article-title>
<source/>Bioinformatics.
          <year>2004</year>
<volume>20</volume>
<issue>3</issue>
<fpage>307</fpage>
<lpage>315</lpage>
<pub-id pub-id-type="doi">10.1093/bioinformatics/btg405</pub-id>
<pub-id pub-id-type="pmid">14960456</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ritchie</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Phipson</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Law</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>W</given-names>
</name>
<etal></etal>
</person-group>
<article-title>limma powers differential expression analyses for RNA-sequencing and microarray studies</article-title>
<source/>Nucleic Acids Res
          <year>2015</year>
<volume>43</volume>
<issue>7</issue>
<fpage>e47</fpage>
<pub-id pub-id-type="doi">10.1093/nar/gkv007</pub-id>
<pub-id pub-id-type="pmid">25605792</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>